Home/Pipeline/CDM® in Alzheimer's Trial (Caladrix C-001)

CDM® in Alzheimer's Trial (Caladrix C-001)

Alzheimer's Disease

Phase 1bActive

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 1b

Status

Active

Company

Oxford Brain Diagnostics

About Oxford Brain Diagnostics

Oxford Brain Diagnostics is a private, commercial-stage diagnostics company leveraging its FDA-cleared and breakthrough-designated MRI biomarker platform to quantify cortical microstructure changes associated with neurodegeneration. Its core technology, CDM®, provides novel endpoints for clinical trials and tools for clinicians, positioning it as a partner for biopharma and a contributor to precision neurology. The company is actively engaged in partnerships and research grants, indicating a transition from technology validation to commercial application in a high-need market.

View full company profile

Therapeutic Areas

Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active